| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4127e0ed74361eb2ba158353b6ef759 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5089
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-912
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-6882
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate |
2020-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05f2f9f685296f379dddb4526b8fe3fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a2af7bec3b04cb1b92ff4cfe543e7e0 |
| publicationDate |
2021-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3165501-A1 |
| titleOfInvention |
Crosslinked pla-based copolymers |
| abstract |
Embodiments described herein relate generally to compounds comprising allyl lactide residues. One aspect described herein relates generally to a compound or a pharmaceutically acceptable salt thereof, comprising allyl lactide residues and lactide residues, wherein the compound or pharmaceutically acceptable salt thereof is substantially free of valerolactone residues. Another aspect relates to a method of incorporating a drug into a compound, comprising: (i) providing a compound or a pharmaceutically acceptable salt thereof, comprising allyl lactide residues and lactide residues, wherein the compound or pharmaceutically acceptable salt thereof is substantially free of valerolactone residues; (ii) incubating the compound and a drug in the presence of a solvent for an incubation period to form a drug-loaded compound; and (iii) separating the drug-loaded compound from the solvent. |
| priorityDate |
2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |